Pub Date : 2023-10-16DOI: 10.1007/s44178-023-00058-5
Rainer J. Klement, Jerome Figueroa, Michael Weigel, Colin E. Champ, Sami Ok, Reinhart A. Sweeney
Abstract Purpose Obesity and insulin resistance appear to worsen prognosis of breast cancer patients. We conducted a feasibility study to test a 5:2 fasting regime in breast cancer patients undergoing radiotherapy. The intervention was rated as beneficial if it would be able to reduce fat mass while significantly improving insulin sensitivity. Methods A total of 13 non-metastatic breast cancer patients were recruited and instructed to completely abstain from food on two non-consecutive days (minimum 24 h) per week during radiotherapy. Body composition was measured weekly by bioimpedance analysis. Blood parameters were assessed before and at the end of radiotherapy. The product of triglycerides and glucose was used as a proxy for insulin sensitivity. A control group on an unspecified standard diet was assigned by propensity score matching. Results A total of twelve patients completed the study. Three patients reported side effects during fasting which were mild (grade 1). Two patients reported feeling bad while fasting, whereas five had a generally good or very good feeling. The fasting group experienced an average decrease of approximately 200 g body mass ( p < 0.0001), 200 g ( p = 0.002) fat mass and 100 g muscle mass ( p = 0.047) per week, resulting in absolute reductions of 2.45 ± 1.19 kg body mass, 1.5 ± 1.6 kg fat mass and 0.7 ± 0.4 kg muscle mass. There was no improvement in insulin sensitivity and other markers of metabolic health except for gamma-glutamyltransferase which decreased by -7 ± 8 U/l. There was also no indication that 5:2 fasting protected against acute skin toxicity. Conclusions 5:2 fasting is safe and feasible for breast cancer patients during radiotherapy and suitable to significantly reduce fat mass, but beneficial metabolic effects could not be confirmed. To improve these results, future studies could combine 5:2 fasting with carbohydrate restriction, increased protein intake and/or exercise. Trial registration Registered on ClinicalTrials.gov under NCT05861362 on May 12, 2023 (retrospectively registered; https://clinicaltrials.gov/ct2/show/NCT05861362 ).
{"title":"Feasibility and metabolic effects of a 5:2 fasting intervention in women with breast cancer during radiotherapy","authors":"Rainer J. Klement, Jerome Figueroa, Michael Weigel, Colin E. Champ, Sami Ok, Reinhart A. Sweeney","doi":"10.1007/s44178-023-00058-5","DOIUrl":"https://doi.org/10.1007/s44178-023-00058-5","url":null,"abstract":"Abstract Purpose Obesity and insulin resistance appear to worsen prognosis of breast cancer patients. We conducted a feasibility study to test a 5:2 fasting regime in breast cancer patients undergoing radiotherapy. The intervention was rated as beneficial if it would be able to reduce fat mass while significantly improving insulin sensitivity. Methods A total of 13 non-metastatic breast cancer patients were recruited and instructed to completely abstain from food on two non-consecutive days (minimum 24 h) per week during radiotherapy. Body composition was measured weekly by bioimpedance analysis. Blood parameters were assessed before and at the end of radiotherapy. The product of triglycerides and glucose was used as a proxy for insulin sensitivity. A control group on an unspecified standard diet was assigned by propensity score matching. Results A total of twelve patients completed the study. Three patients reported side effects during fasting which were mild (grade 1). Two patients reported feeling bad while fasting, whereas five had a generally good or very good feeling. The fasting group experienced an average decrease of approximately 200 g body mass ( p < 0.0001), 200 g ( p = 0.002) fat mass and 100 g muscle mass ( p = 0.047) per week, resulting in absolute reductions of 2.45 ± 1.19 kg body mass, 1.5 ± 1.6 kg fat mass and 0.7 ± 0.4 kg muscle mass. There was no improvement in insulin sensitivity and other markers of metabolic health except for gamma-glutamyltransferase which decreased by -7 ± 8 U/l. There was also no indication that 5:2 fasting protected against acute skin toxicity. Conclusions 5:2 fasting is safe and feasible for breast cancer patients during radiotherapy and suitable to significantly reduce fat mass, but beneficial metabolic effects could not be confirmed. To improve these results, future studies could combine 5:2 fasting with carbohydrate restriction, increased protein intake and/or exercise. Trial registration Registered on ClinicalTrials.gov under NCT05861362 on May 12, 2023 (retrospectively registered; https://clinicaltrials.gov/ct2/show/NCT05861362 ).","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":"137 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136113834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-25DOI: 10.1007/s44178-023-00054-9
Lei Gong, Ming Bai, Liang Dai, Xufeng Guo, Xuefeng Leng, Zhigang Li, Zhihao Lu, Teng Mao, Qingsong Pang, Lin Shen, Yifeng Sun, Hong Yang, Jun Yin, Hongdian Zhang, Wencheng Zhang, Gang Zhao, Bin Zheng, Yueyang Yang, Yi Ba, Chun Chen, Haiquan Chen, Longqi Chen, Ting Deng, Qingxia Fan, Wentao Fang, Xiangning Fu, Jing Huang, Xiaofei Li, Yin Li, Shuoyan Liu, Yongyu Liu, Jianqun Ma, Weimin Mao, Jingli Ren, Lijie Tan, Peng Tang, Lvhua Wang, Qun Wang, Wenqiang Wei, Qi Xue, Renquan Zhang, Keneng Chen, Jianhua Fu, Junfeng Liu, Yongtao Han, Jie He, Zhentao Yu, Yousheng Mao
Abstract Esophageal carcinoma (EC) is a common malignant tumor of the upper digestive tract worldwide. An analysis of the latest data from cancer centers in China showed that the incidence of EC and the number of deaths due to EC in China in 2015 were 266,000 and 188,000, respectively, ranking sixth (6.3%) and fourth (8.0%) among all malignant tumors. The early diagnosis and treatment of EC and standardized diagnosis and treatment are important tasks for EC healthcare professionals in various centers across the country. At present, the 8th edition of the EC staging system jointly released by Union for International Cancer Control (UICC) and American Joint Committee on Cancer (AJCC) is the most recent, authoritative and widely used EC staging standard. The EC professional committee of the Chinese Anti-Cancer Association also organizes the "EC Standardization Campaign in China" every year to promote the development of EC diagnostic and treatment norms throughout the country. Since 2011, the EC Committee of the Chinese Anti-Cancer Association has published the Guidelines for Standardized Diagnosis and Treatment of EC. Considering the increasing number of EC clinical studies and the continuous progress in diagnostic and treatment technologies in recent years, the updated Guidelines will include the latest progress in the diagnosis and treatment of EC, with a goal of promoting the forward development of EC diagnosis and treatment in clinical practice.
{"title":"CACA guidelines for holistic integrative management of esophageal carcinoma","authors":"Lei Gong, Ming Bai, Liang Dai, Xufeng Guo, Xuefeng Leng, Zhigang Li, Zhihao Lu, Teng Mao, Qingsong Pang, Lin Shen, Yifeng Sun, Hong Yang, Jun Yin, Hongdian Zhang, Wencheng Zhang, Gang Zhao, Bin Zheng, Yueyang Yang, Yi Ba, Chun Chen, Haiquan Chen, Longqi Chen, Ting Deng, Qingxia Fan, Wentao Fang, Xiangning Fu, Jing Huang, Xiaofei Li, Yin Li, Shuoyan Liu, Yongyu Liu, Jianqun Ma, Weimin Mao, Jingli Ren, Lijie Tan, Peng Tang, Lvhua Wang, Qun Wang, Wenqiang Wei, Qi Xue, Renquan Zhang, Keneng Chen, Jianhua Fu, Junfeng Liu, Yongtao Han, Jie He, Zhentao Yu, Yousheng Mao","doi":"10.1007/s44178-023-00054-9","DOIUrl":"https://doi.org/10.1007/s44178-023-00054-9","url":null,"abstract":"Abstract Esophageal carcinoma (EC) is a common malignant tumor of the upper digestive tract worldwide. An analysis of the latest data from cancer centers in China showed that the incidence of EC and the number of deaths due to EC in China in 2015 were 266,000 and 188,000, respectively, ranking sixth (6.3%) and fourth (8.0%) among all malignant tumors. The early diagnosis and treatment of EC and standardized diagnosis and treatment are important tasks for EC healthcare professionals in various centers across the country. At present, the 8th edition of the EC staging system jointly released by Union for International Cancer Control (UICC) and American Joint Committee on Cancer (AJCC) is the most recent, authoritative and widely used EC staging standard. The EC professional committee of the Chinese Anti-Cancer Association also organizes the \"EC Standardization Campaign in China\" every year to promote the development of EC diagnostic and treatment norms throughout the country. Since 2011, the EC Committee of the Chinese Anti-Cancer Association has published the Guidelines for Standardized Diagnosis and Treatment of EC. Considering the increasing number of EC clinical studies and the continuous progress in diagnostic and treatment technologies in recent years, the updated Guidelines will include the latest progress in the diagnosis and treatment of EC, with a goal of promoting the forward development of EC diagnosis and treatment in clinical practice.","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":"59 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135817498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-06DOI: 10.1007/s44178-023-00056-7
Donghui Jin, Yousheng Mao
{"title":"Recent advances in the mechanisms of development and the early diagnosis and treatment of esophageal cancer","authors":"Donghui Jin, Yousheng Mao","doi":"10.1007/s44178-023-00056-7","DOIUrl":"https://doi.org/10.1007/s44178-023-00056-7","url":null,"abstract":"","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44765501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-05DOI: 10.1007/s44178-023-00055-8
Ke Ji, Jia-Fu Ji
{"title":"Current status of immunotherapy in gastric cancer","authors":"Ke Ji, Jia-Fu Ji","doi":"10.1007/s44178-023-00055-8","DOIUrl":"https://doi.org/10.1007/s44178-023-00055-8","url":null,"abstract":"","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45440177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-25DOI: 10.1007/s44178-023-00053-w
Han-Fei Guo, Bin Wang, Wen-Qian Li, N. Chen, Jiuwei Cui
{"title":"Current landscape and challenges ahead of immuno-molecular mechanism and immunotherapy strategy of brain metastases","authors":"Han-Fei Guo, Bin Wang, Wen-Qian Li, N. Chen, Jiuwei Cui","doi":"10.1007/s44178-023-00053-w","DOIUrl":"https://doi.org/10.1007/s44178-023-00053-w","url":null,"abstract":"","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44632368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-22DOI: 10.1007/s44178-023-00051-y
Shuliang Zhang, Yizhou Huang, Maohui Chen, T. Zeng, Guang-Chang Huang, Wei Zheng, Wei Li, C. Chen, B. Zheng
{"title":"Results of robot-assisted minimally invasive esophagectomy in 111 consecutive patients: an Asia cohort study","authors":"Shuliang Zhang, Yizhou Huang, Maohui Chen, T. Zeng, Guang-Chang Huang, Wei Zheng, Wei Li, C. Chen, B. Zheng","doi":"10.1007/s44178-023-00051-y","DOIUrl":"https://doi.org/10.1007/s44178-023-00051-y","url":null,"abstract":"","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45869757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-04DOI: 10.1007/s44178-023-00052-x
Qiang Wang, Hui Liu, Xufeng Guo
{"title":"A case–control study on early removal of thoracic drainage tube and gastric tube after MIE","authors":"Qiang Wang, Hui Liu, Xufeng Guo","doi":"10.1007/s44178-023-00052-x","DOIUrl":"https://doi.org/10.1007/s44178-023-00052-x","url":null,"abstract":"","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48801621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-31DOI: 10.1007/s44178-023-00050-z
Zerui Zhao, Zhichao Li, Wei-zhao Huang, Gen-jie Wang, T. Mao, Wenqiang Lv, Lin Peng, Jiyang Chen, Han Yang
{"title":"Fibrin sealant for the prevention of anastomotic leakage after esophagectomy for esophageal or esophagogastric junction cancer: interim report of a prospective, phase III, randomized controlled study","authors":"Zerui Zhao, Zhichao Li, Wei-zhao Huang, Gen-jie Wang, T. Mao, Wenqiang Lv, Lin Peng, Jiyang Chen, Han Yang","doi":"10.1007/s44178-023-00050-z","DOIUrl":"https://doi.org/10.1007/s44178-023-00050-z","url":null,"abstract":"","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48340561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：